{"id":"W4362472973","doi":"10.1016/j.msard.2022.104360","title":"MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Placebo; Multiple sclerosis; Double blind; Magnetic resonance imaging; Internal medicine; Nuclear medicine; Tolerability; Gastroenterology; Adverse effect; Pathology; Immunology; Radiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002119198,0.0008392232,0.001637574,0.0003077498,0.0003934517,0.001011589,0.000440486,0.001211117,0.002041593],"category_scores_gemma":[0.002812654,0.0002761911,0.001397191,0.0003810167,0.0006646449,0.001237914,0.0003123957,0.002077119,0.0004172909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007463995,"about_ca_system_score_gemma":0.0005840211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001579349,"about_ca_topic_score_gemma":0.002230695,"domain_scores_codex":[0.9993066,0.0003191154,0.00004759898,0.00009293016,0.00006112076,0.00017265],"domain_scores_gemma":[0.9984902,0.0003402257,0.0004470728,0.0001093062,0.0001788739,0.0004342959],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8417133,0.007493909,0.04144569,0.0007838072,0.005462953,0.0003921354,0.0002237253,0.002589487,0.007871091,0.0002907269,0.005169375,0.08656383],"study_design_scores_gemma":[0.2150024,0.2782404,0.4739248,0.000436582,0.01063738,0.001691887,0.0004482561,0.004129043,0.004037065,0.002341864,0.008903186,0.0002071645],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897438,0.006643915,0.0001569953,0.0005628554,0.0001413309,0.00009894802,0.0009083762,0.00002383672,0.001719921],"genre_scores_gemma":[0.9960036,0.001195019,0.0001131255,0.0003913325,0.0001524342,0.00008878038,0.001348869,0.000007498275,0.0006993818],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002119198,"threshold_uncertainty_score":0.01120752,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09464708955712986,"score_gpt":0.3631750525634793,"score_spread":0.2685279630063495,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}